TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$69 Million


Convertible Debt

Exclusive Financial Advisor, January 2021

Convertible Notes Restructuring

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT technology to generate improved prodrug versions of drugs approved by the FDA, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm’s prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, stimulant use disorder (SUD) andidiopathic hypersomnia (IH).